All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 29, 2023
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

3D model of coronavirus spike

Not yet a pandemic, 2019-nCoV has echoes of MERS, SARS, flu

Feb. 5, 2020
By Anette Breindl
No Comments
The drug screens prompted by the SARS and MERS outbreaks have been useful for quickly identifying drug candidates. But in terms of their epidemiology, “SARS and MERS were different from this coronavirus,” Allison McGeer explained at a Feb. 3 webinar by Evercore ISI.
Read More

Gilead investor sentiment remains flat amid continued focus on next steps

Feb. 5, 2020
By Michael Fitzhugh
No Comments
Modest revenue growth and a 2020 outlook that left analysts uninspired about its near-term prospects pushed Gilead Sciences Inc. shares (NASDAQ:GILD) down about 2% to close Feb. 5 at $65.87, despite growing sales of its HIV medicine, Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide), and what CEO Daniel O'Day called "a sense of urgency" around further business development.
Read More

Regulatory front for Feb. 5, 2020

Feb. 5, 2020
No Comments
The latest global regulatory news, changes and updates affecting biopharma, including: Raregen, Sandoz, United.
Read More
Coronavirus microscopic model
Ebola, malaria, HIV, TCM

Researchers cast wide net for rapid-draw weapons in 2019-nCoV fight

Feb. 4, 2020
By Anette Breindl
No Comments
At this very early point in the emerging 2019-nCoV outbreak, knowledge about the virus is insufficient to predict what shape that outbreak will ultimately take. But knowledge about the virus is accumulating at remarkable speed, and experience with other viruses is helping to shape the response to the newest coronavirus threat. 2019-nCoV, sometimes called Wuhan coronavirus after its source, is the third coronavirus after SARS-CoV and MERS-CoV with the potential to cause serious illness and death that has emerged since the beginning of the 21st century.
Read More

Preventing a U.S. outbreak: Emergency declaration leads to hunt for more funding

Feb. 4, 2020
By Mari Serebrov
No Comments
Now that U.S. Health and Human Services (HHS) Secretary Alex Azar has declared a nationwide public health emergency due to the 2019 novel coronavirus (2019-nCoV), HHS is saying it may need more money to help it be as proactive and aggressive as possible in detecting the virus and containing an outbreak.
Read More
Traditional Chinese medicine illustration

Coronavirus: Chinese researchers claim TCM herbal remedy could ‘inhibit’ 2019-nCoV

Feb. 4, 2020
By Cornelia Zou
No Comments
HONG KONG – In another example that communication is proving as difficult as containment in the current coronavirus outbreak, China’s state media reported, to increasing skepticism, that a traditional Chinese medicine (TCM) oral liquid could inhibit the new coronavirus.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
No Comments
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: Advaccine, Anticancer, Asahi Kasei, Aspen, Avacta, BGI, Biolexis, Celularity, Clover, Curetis, Curevac, Daewoong, Duke-National University, Horizon, Inovio, Novartis, Outlook, Oxford Gene Technology, Sandoz, Sorrento, Sysmex, Takeda, Veloxis, Wuhan Institute of Virology, Wuxi Biologics.
Read More

Regulatory front for Feb. 4, 2020

Feb. 4, 2020
No Comments
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: GE Healthcare.
Read More

Other news to note for Feb. 4, 2020

Feb. 4, 2020
No Comments
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aevi Genomics, Anika, Anteros, Athenex, Arthrosurface, Beijing CC-Pharming, Biomotiv, Biosense Webster, BMS, Boehringer, Cerecor, Contrafect, Cormedix, CNS Pharmaceuticals, Equinox, Eyepoint, FSD, Genekam, Ibio, Inprother, Levena, Mablytics, Navrogen, Pattern Bioscience, Plex, Porton Pharma, Q Biomed, Rhythm AI, Salarius, Samus, Sirion, Solarvest, Syntrix, Theratechnologies, Trefoil, Trianni.
Read More
2-3-Azar-HHS.png

HHS declares public health emergency in part because CDC test for coronavirus unreliable

Feb. 3, 2020
By Mark McCarty
No Comments
The U.S. Department of Health and Human Services has declared a public health emergency in the U.S. over the coronavirus in part because a government diagnostic for the virus yields inconsistent results, a fact that may spur the life sciences to provide a solution.
Read More
Previous 1 2 … 473 474 475 476 477 478 479 480 481 … 495 496 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan. 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 27, 2022.
  • Biogen, Eisai win FDA clearance for AD therapy Leqembi

    BioWorld
    As expected, the U.S. FDA gave its go-ahead to lecanemab, an amyloid-beta binder for mild cognitive impairment caused by Alzheimer’s disease (AD) and mild AD –...
  • Stem-cells2.png

    J.P. Morgan Healthcare Conference: ‘Bright’ year ahead for cell, gene therapies, says ARM

    BioWorld
    After long years of painstaking work, the commercialization of cell and gene therapies picked up pace in 2022, with multiple approvals. More progress is expected...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing